A Randomized, Controlled, Multicenter, Open-label Trial Comparing a Hospital Post-discharge Care Pathway Involving Aggressive LDL-C Management That Includes Inclisiran With Usual Care Versus Usual Care Alone in Patients With a Recent Acute Coronary Syndrome(VICTORION-INCEPTION)
Latest Information Update: 28 Nov 2024
Price :
$35 *
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms V-INCEPTION; VICTORION-INCEPTION
- Sponsors Novartis
- 25 Nov 2024 Status changed from active, no longer recruiting to completed.
- 27 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 18 Jul 2023 Planned primary completion date changed from 7 Jun 2023 to 30 Aug 2024.